
Atara Biotherapeutics, Inc.: updates and filings
Price
$6.50
November 17, 2026Market cap $100M
What Ploutos Investor adds for Atara Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Shelf registration for future offeringsFormS-3
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 24, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 26, 2026Officer or director changeForm8-K
- Jun 12, 2026Shares registered for employeesFormS-8
- Jun 12, 2026Officer or director change, shareholder voteForm8-K
- May 14, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Financial statements and exhibitsForm8-K
- May 11, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 8, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Other material eventsForm8-K
- May 1, 2026Delisting noticeForm8-K
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Mar 25, 2026FilingFormEFFECT
- Mar 23, 2026Correspondence with the SECFormCORRESP
- Mar 20, 2026Letter from the SECFormUPLOAD
- Mar 17, 2026Shelf registration for future offeringsFormS-3
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 24, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 26, 2026 | 8-K | Officer or director change | Document |
| Jun 12, 2026 | S-8 | Shares registered for employees | Document |
| Jun 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 14, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Financial statements and exhibits | Document |
| May 11, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 8, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 8-K | Other material events | Document |
| May 1, 2026 | 8-K | Delisting notice | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 25, 2026 | EFFECT | Filing | Document |
| Mar 23, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 20, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 17, 2026 | S-3 | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 10, 2014.
The full analysis
What do Atara Biotherapeutics's filings show?
The filings are where every one of Atara Biotherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.